Please use this identifier to cite or link to this item:
Title: Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
Author: Saponaro, Mariarosaria
Annunziata, Luigi
Turla, Antonella
Viganò, Ilaria
Laurentiis, Michele De
Giuliano, Mario
Mastro, Lucia del
Montemurro, Filippo
Puglisi, Fabio
Angelis, Carmine De
Buono, Giuseppe
Schettini, Francesco
Arpino, Grazia
Keywords: Càncer de mama
Tractament adjuvant del càncer
Receptors d'hormones
Efectes secundaris
Breast cancer
Adjuvant treatment of cancer
Hormone therapy
Hormone receptors
Side effects
Issue Date: 6-Nov-2022
Publisher: MDPI
Abstract: In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.
Note: Reproducció del document publicat a:
It is part of: International Journal of Molecular Sciences, 2022, vol. 23, num. 21, p. 13604
Related resource:
ISSN: 1661-6596
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
729774.pdf314.22 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons